The advent of high-throughput molecular analysis has appreciably improved the diagnostic and prognostic workup of several types of cancer. A French study now offers hope that benign and malignant adrenocortical tumors can be distinguished on the basis of distinct differences in their gene-expression profiles.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de Reyniès, A. et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108–1115 (2009).
Allolio, B. & Fassnacht, M. Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 91, 2027–2037 (2006).
DeLellis, R. A., Lloyd, R. V., Heitz, P. U. & Eng, C. (eds) Pathology and Genetics of Tumours of Endocrine Organs (IARC WHO Classification of Tumours) (IARC Press, Lyon, 2004).
Fassnacht, M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009).
Volante, M., Buttigliero, C., Greco, E., Berruti, A. & Papotti, M. Pathological and molecular features of adrenocortical carcinoma: an update. J. Clin. Pathol. 61, 787–793 (2008).
Giordano, T. J. et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668–676 (2009).
First International Randomized trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT), firm act study [online] (2009).
Ronchi, C. et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr. Relat. Cancer doi:10.1677/ERC-08-0224 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Betz, M., Beuschlein, F. Novel molecular signatures for adrenocortical carcinoma. Nat Rev Endocrinol 5, 297–299 (2009). https://doi.org/10.1038/nrendo.2009.93
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.93
